Novacap completes acquisition of PCI

With the purchase, the company expands its pharmaceutical offerings in the U.S.

Register for free to listen to this article
Listen with Speechify
LYON, France & NEWBURYPORT, Mass.—Novacap, a worldwide player in pharmaceutical synthesis and advanced specialties, announced in late June that it had completed the acquisition of PCI Synthesis. PCI Synthesis is a leading U.S. pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of services, including process research and early-stage development as well as commercial production of new chemical entities, generic active pharmaceutical ingredients and other specialty chemical products.
The combination of the two companies will provide PCI Synthesis with additional resources to continue its development while reinforcing Novacap’s global leadership in pharmaceutical synthesis with 12 cGMP sites, two main R&D centers and its comprehensive range of services and technologies dedicated to clinical development and commercial manufacturing.
“Since we started the company more than 20 years ago, we’ve continued to evolve and innovate, and by teaming with Novacap, we will continue to do so, now with access to Novacap’s deep technical expertise to better serve our customers," said Ed Price, founder and president of PCI Synthesis.
“The acquisition of PCI Synthesis perfectly fits with our strategic roadmap, as it will strengthen our offerings to the pharmaceutical industry and provide Novacap with a strong and innovative platform to accelerate our development in the U.S. We have been impressed by the outstanding achievement of PCI Synthesis over the last years and its promising pipeline of projects. The two companies operate complementary CDMO activities and share common values such as entrepreneurship, operational excellence and dedication to customer satisfaction. We look forward to working with the PCI Synthesis team,” said Pierre Luzeau, CEO of Novacap.

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue